Overview
Biotech firm reported Q4 2025 net loss of $102.5 mln, increased from last year
Company maintains strong cash position with $901 mln, funding operations into 2028
Bezuclastinib NDA submissions on track for 2026, including AdvSM and GIST indications
Outlook
Cogent plans to submit APEX NDA for bezuclastinib in 1H 2026
Company aims to launch bezuclastinib in second half of 2026
Cogent expects cash runway to support operations into 2028
Result Drivers
NDA SUBMISSIONS - Cogent submitted SUMMIT NDA for bezuclastinib in NonAdvSM and initiated PEAK NDA for GIST under RTOR program
CLINICAL TRIAL PROGRESS - Bezuclastinib showed clinical benefits in SUMMIT and APEX trials, with significant symptom improvements and high response rates
FINANCIAL POSITION - Cogent maintains strong cash reserves of $901 mln, supporting operations into 2028
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Income | -$102.49 mln | ||
Q4 Income from Operations | -$99.49 mln | ||
Q4 Operating Expenses | $99.49 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cogent Biosciences Inc is $50.50, about 38.2% above its February 13 closing price of $36.53
Press Release: ID:nGNX28xgdW
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)